23 Jul, 2026
According to Straits Research, the global erythropoietin drugs market size was valued at $7.55 billion in 2025 and is projected to reach $10.35 billion by 2034, at a CAGR of 3.61% during the forecast period 2026–2034.
The growth of the global erythropoietin drugs market is primarily driven by the rising prevalence of chronic kidney disease (CKD), a major condition that leads to anemia due to reduced endogenous erythropoietin production. As the global burden of CKD continues to increase, the demand for erythropoietin-based therapies is witnessing strong momentum. For example, according to the Centers for Disease Control and Prevention, approximately 35.5 million adults in the U.S. are currently living with CKD, highlighting a substantial patient population requiring anemia management. This growing clinical need is fostering the widespread adoption of erythropoietin drugs to enhance hemoglobin levels and improve patient outcomes.
Moreover, the market is experiencing expansion through the increasing approval and commercialization of erythropoietin biosimilars, which offer comparable efficacy and safety profiles at significantly reduced costs. These cost effective alternatives are particularly improving treatment accessibility in emerging economies such as Asia Pacific and Latin America, where healthcare affordability remains a critical factor.
However, the risk of adverse effects associated with erythropoietin therapy, such as hypertension, cardiovascular complications, and increased thrombotic events, limits long term treatment adherence. Additionally, stringent regulatory requirements for biosimilar approvals and manufacturing challenges related to maintaining product quality and consistency further constrain market growth. On the other hand, the ongoing shift toward biosimilars, coupled with advancements in biomanufacturing and growing healthcare infrastructure in developing regions, is expected to create lucrative opportunities for key players to expand their global footprint in the erythropoietin drugs market.
Asia Pacific is emerging as the fastest-growing region with a CAGR of 5.13% from 2026-2034, owing to the rising prevalence of chemotherapy induced anemia among cancer patients. Increasing cancer incidence, coupled with wider adoption of chemotherapy treatments, is boosting the demand for erythropoietin therapies to manage anemia and improve patient treatment outcomes.
Europe is witnessing steady market growth driven by the establishment of mandatory pharmacovigilance registries and evidence frameworks that ensure rigorous monitoring of biosimilar safety and efficacy. These regulatory initiatives are strengthening clinician confidence in erythropoietin biosimilars, encouraging their adoption across healthcare systems, and fostering sustainable market expansion through increased trust and competitive pricing.
sales@straitsresearch.com